Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Miguel Jhonatan Sotelo Lezama, Javier Sastre Valera & Eduardo Díaz-Rubio García. (2014) Impact of cetuximab in current treatment of metastatic colorectal cancer. Expert Opinion on Biological Therapy 14:3, pages 387-399.
Read now
Read now
Articles from other publishers (41)
Se-Hee Kim, Sangtae Choi & Won-Suk Lee. (2021) Bevacizumab and anexelekto inhibitor, TP-0903 inhibits TGF-β1-induced epithelial–mesenchymal transition of colon cancer cells. Anti-Cancer Drugs 33:1, pages e453-e461.
Crossref
Crossref
Shahenda Mahgoub, Hadeer Abosalem, Mohamed Emara, Nahla Kotb, A. Maged & Sameh Soror. (2021) Restoring NK cells functionality via cytokine activation enhances cetuximab-mediated NK-cell ADCC: A promising therapeutic tool for HCC patients. Molecular Immunology 137, pages 221-227.
Crossref
Crossref
Zaihua Yan, Peidong Li, Yuan Xue, Hongpeng Tian, Tong Zhou & Guangjun Zhang. (2021) Glutamate receptor, ionotropic, N‑methyl D‑aspartate‑associated protein 1 promotes colorectal cancer cell proliferation and metastasis, and is negatively regulated by miR‑296‑3p. Molecular Medicine Reports 24:4.
Crossref
Crossref
Hadeer Abosalem, Shahenda Mahgoub, Mohamed Emara, Nahla Kotb & Sameh Soror. (2021) Interrupted Crosstalk between Natural Killer Cells and Anti-epidermal Growth Factor Receptor: A Possible Role in Hepatocellular Carcinoma Treatment Failure. Current Cancer Drug Targets 21:7, pages 601-607.
Crossref
Crossref
Yi-Hsin Liang, Jia-Huei Tsai, Yung-Ming Cheng, Kuang-Yu Chan, Wen-Ling Hsu, Chang-Cheng Lee, Kuo-Hsing Chen & Kun-Huei Yeh. (2021) Chemotherapy agents stimulate dendritic cells against human colon cancer cells through upregulation of the transporter associated with antigen processing. Scientific Reports 11:1.
Crossref
Crossref
Lena-Christin Conradi, Melanie Spitzner, Anna-Lena Metzger, Merle Kisly, Peter Middel, Hanibal Bohnenberger, Jochen Gaedcke, Michael B. Ghadimi, Torsten Liersch, Joseph Rüschoff, Tim Beißbarth, Alexander König & Marian Grade. (2019) Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer. BMC Cancer 19:1.
Crossref
Crossref
Karin Bartel, Rolf Müller & Karin von Schwarzenberg. (2019) Differential regulation of AMP-activated protein kinase in healthy and cancer cells explains why V-ATPase inhibition selectively kills cancer cells. Journal of Biological Chemistry 294:46, pages 17239-17248.
Crossref
Crossref
Xuepeng Fan, Mei Liu, Hao Tang, Dewen Leng, Shuli Hu, Rong Lu, Weibo Wan & Shiying Yuan. (2019) MicroRNA-7 Exerts Antiangiogenic Effect on Colorectal Cancer via ERK Signaling. Journal of Surgical Research 240, pages 48-59.
Crossref
Crossref
Guoqiang Rong, Xiaodong Yang, Haorong Wu & Yongyou Wu. (2018) miR‐150‐504‐519d inhibits the growth of human colorectal cancer cell line SW48 and downregulates c‐FLIP receptor. Journal of Cellular Biochemistry 120:5, pages 7962-7969.
Crossref
Crossref
Liuliu Zhang, Yi Zhang, Huayun Zhu, Xiaofeng Sun, Xiaohua Wang, Pingping Wu & Xinyu Xu. (2018) Overexpression of miR‐301a‐3p promotes colorectal cancer cell proliferation and metastasis by targeting deleted in liver cancer‐1 and runt‐related transcription factor 3. Journal of Cellular Biochemistry 120:4, pages 6078-6089.
Crossref
Crossref
Seongjin Lim, Hyeono Nam & Jessie S. Jeon. (2018) Chemotaxis Model for Breast Cancer Cells Based on Signal/Noise Ratio. Biophysical Journal 115:10, pages 2034-2043.
Crossref
Crossref
Andrew G. Hill, Michael P. Findlay, Matthew E. Burge, Christopher Jackson, Pilar Garcia Alfonso, Leslie Samuel, Vinod Ganju, Meinolf Karthaus, Alessio Amatu, Mark Jeffery, Maria Di Bartolomeo, John Bridgewater, Andrew L. Coveler, Manuel Hidalgo, Amy V. Kapp, Roxana I. Sufan, Bruce B. McCall, William D. Hanley, Elicia M. Penuel, Andrea Pirzkall & Josep Tabernero. (2018)
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line
RAS
Wild-Type Metastatic Colorectal Cancer
. Clinical Cancer Research 24:10, pages 2276-2284.
Crossref
Crossref
Karin Alvarez, Paulina Orellana, Cynthia Villarroel, Luis Contreras, Hiroshi Kawachi, Maki Kobayashi, Ana Maria Wielandt, Marjorie De la Fuente, Juan Carlos Triviño, Udo Kronberg, Pilar Carvallo & Francisco López-Köstner. (2017) EGFR pathway subgroups in Chilean colorectal cancer patients, detected by mutational and expression profiles, associated to different clinicopathological features. Tumor Biology 39:9, pages 101042831772451.
Crossref
Crossref
Fang GengZheng WangHang YinJunxian YuBangwei Cao. (2017) Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives. Cancer Biotherapy and Radiopharmaceuticals 32:5, pages 149-160.
Crossref
Crossref
Erika Martinelli, Floriana Morgillo, Teresa Troiani & Fortunato Ciardiello. (2017) Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. Cancer Treatment Reviews 53, pages 61-69.
Crossref
Crossref
Shanshan Chen, Xuechun Li, Rongming Chen, Mingang Yin & Qiuhong Zheng. (2016) Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model. Oncology Letters 12:3, pages 1868-1876.
Crossref
Crossref
Udo S. Gaipl. (2016) EGFR-Inhibition bei NSCLC-TumorzelllinienEGFR inhibition in NSCLC tumor cell lines. Strahlentherapie und Onkologie 192:6, pages 425-427.
Crossref
Crossref
Giovanna Mirone, Arvind Shukla & Gabriella Marfe. (2016) Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer. Critical Reviews in Oncology/Hematology 97, pages 85-95.
Crossref
Crossref
Elena López-Knowles, Paul M Wilkerson, Ricardo Ribas, Helen Anderson, Alan Mackay, Zara Ghazoui, Aradhana Rani, Peter Osin, Ash Nerurkar, Lorna Renshaw, Alexey Larionov, William R Miller, J Michael Dixon, Jorge S Reis-Filho, Anita K Dunbier, Lesley-Ann Martin & Mitch Dowsett. (2015) Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer. Breast Cancer Research 17:1.
Crossref
Crossref
Guang-jun Zhang, Jian-shui Li, He Zhou, Hua-xu Xiao, Yu Li & Tong Zhou. (2015) MicroRNA-106b promotes colorectal cancer cell migration and invasion by directly targeting DLC1. Journal of Experimental & Clinical Cancer Research 34:1.
Crossref
Crossref
Zhenlei Wang, Bin Ma, Xiaopin Ji, Yang Deng, Tao Zhang, Xiaojian Zhang, Haoji Gao, Hanxing Sun, Haoxuan Wu, Xianze Chen & Ren Zhao. (2015) MicroRNA-378-5p suppresses cell proliferation and induces apoptosis in colorectal cancer cells by targeting BRAF. Cancer Cell International 15:1.
Crossref
Crossref
Yu Chen, Yi Shi, Jing Lin, Yun-bin Ye, Xiao-jie Wang, Gang Chen & Zeng-qing Guo. (2015) Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer. Medicine 94:40, pages e1698.
Crossref
Crossref
Xin-Xiang Li, Lei Liang, Li-Yong Huang & San-Jun Cai. (2015) Standard chemotherapy with cetuximab for treatment of colorectal cancer. World Journal of Gastroenterology 21:22, pages 7022-7035.
Crossref
Crossref
Julianne D. Twomey, Su-Ryun Kim, Liqun Zhao, William P. Bozza & Baolin Zhang. (2015) Spatial dynamics of TRAIL death receptors in cancer cells. Drug Resistance Updates 19, pages 13-21.
Crossref
Crossref
Bo Gong. (2015)
MiR-21/RASA1 axis affects malignancy of colon cancer cells
via
RAS pathways
. World Journal of Gastroenterology 21:5, pages 1488.
Crossref
Crossref
Hisato Kawakami, Isamu Okamoto, Kimio Yonesaka, Kunio Okamoto, Kiyoko Shibata, Yume Shinkai, Haruka Sakamoto, Michiko Kitano, Takao Tamura, Kazuto Nishio & Kazuhiko Nakagawa. (2014) The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget 5:23, pages 11847-11856.
Crossref
Crossref
Wen-Cui Ju, Guo-Bin Huang, Xiao-Yong Luo, Wei-Hua Ren, De-Qing Zheng, Pin-Jia Chen, Yun-Feng Lou & Bin Li. (2014) X-linked inhibitor of apoptosis-associated factor l (XAFl) enhances the sensitivity of colorectal cancer cells to cisplatin. Medical Oncology 31:12.
Crossref
Crossref
Onat Kadioglu, Ean Jeong Seo & Thomas Efferth. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
823
850
.
Erika Martinelli, Stefania Napolitano, Davide Ciardiello, Fortunato Ciardiello & Teresa Troiani. (2014) Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer. Current Colorectal Cancer Reports 10:3, pages 279-287.
Crossref
Crossref
Teresa Troiani, Filippo Venturini, Stefania Napolitano, Giulia Martini, Valentina Gambardella, Fortunato Ciardiello & Erika Martinelli. (2014) Predictive biomarkers to anti-EGF receptor inhibitors in the treatment of metastatic colorectal cancer. Colorectal Cancer 3:3, pages 299-308.
Crossref
Crossref
Alaaeldin Shablak & Andrew Conn. (2013) A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment. Targeted Oncology 9:2, pages 177-180.
Crossref
Crossref
Dong Chen, Jun-Fu Huang, Han Xia, Guang-Jie Duan, Zheng-Ran Chuai, Zhao Yang, Wei-Ling Fu & Qing Huang. (2014) High-sensitivity PCR method for detecting BRAF V600Emutations in metastatic colorectal cancer using LNA/DNA chimeras to block wild-type alleles. Analytical and Bioanalytical Chemistry 406:9-10, pages 2477-2487.
Crossref
Crossref
Siddhartha Deb & Stephen B Fox. (2014) Molecular profiling in colorectal cancer: current state of play and future directions. Colorectal Cancer 3:1, pages 41-56.
Crossref
Crossref
Wenhao Weng, Junlan Feng, Huanlong Qin & Yanlei Ma. (2014) Molecular therapy of colorectal cancer: Progress and future directions. International Journal of Cancer, pages n/a-n/a.
Crossref
Crossref
Elena Tsvetkova & Timothy R. Asmis. (2013) How Do We Make Choices in Salvage Therapy: Panitumumab, Cetuximab, or Regorafenib?. Current Colorectal Cancer Reports 9:4, pages 326-330.
Crossref
Crossref
Jung-Jin Park & Minyoung Lee. (2013) Increasing the α 2, 6 Sialylation of Glycoproteins May Contribute to Metastatic Spread and Therapeutic Resistance in Colorectal Cancer. Gut and Liver 7:6, pages 629-641.
Crossref
Crossref
Sing Yu Moorcraft, Elizabeth C. Smyth & David Cunningham. (2013) The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. Therapeutic Advances in Gastroenterology 6:5, pages 381-395.
Crossref
Crossref
Santu Kumar Saha & Anisur Rahman Khuda-Bukhsh. (2013) Molecular approaches towards development of purified natural products and their structurally known derivatives as efficient anti-cancer drugs: Current trends. European Journal of Pharmacology 714:1-3, pages 239-248.
Crossref
Crossref
Yuriko Ito, Yasuhide Yamada, Kiyoshi Asada, Toshikazu Ushijima, Satoru Iwasa, Ken Kato, Tetsuya Hamaguchi & Yasuhiro Shimada. (2013) EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients. Journal of Cancer Research and Clinical Oncology 139:8, pages 1391-1396.
Crossref
Crossref
Jan B VermorkenChristian RolfoGiuseppe BronteAntonio RussoMarc Peeters. 2013. Monoclonal Antibodies Targeting EGFR/HER2 and Clinical Outcomes in Cancer Treatment. Monoclonal Antibodies Targeting EGFR/HER2 and Clinical Outcomes in Cancer Treatment
10
26
.
Lei Zhu, Lin Zhao, Meizhi Wu, Zhange Chen & Huangjin Li. (2013) B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR). Immunology Letters 153:1-2, pages 33-40.
Crossref
Crossref